PRGO
Perrigo Company plc · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:40 UTC
Last close
15.83USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-26
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
-33.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
3.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
1.30Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
7.3%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2025, filed 2026-02-26
Growth is the furthest below its sector's middle: 0.11 against 0.50 on the market's range.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 2- Profit on each unit of sales-33.5%1.5%Behind
Higher is better here.
- Return on the capital it usesn/a3.1%n/a
Higher is better here.
- Sales growth over five years0.8%5.0%Behind
Higher is better here.
- Debt against equity1.30n/an/a
Lower is better here.
- Gross margin35.1%n/an/a
Higher is better here.
- Price against earningsn/a19.5xn/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Bausch Health Companies Inc., PRGO is behind on 2 of 2 measures.
Against Bausch Health Companies Inc., PRGO is behind on 2 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales-33.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
Sales growth over five years0.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
Debt against equity1.30
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
Gross margin35.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001585364-26-000009
- Reported in
- USD